Viatris (VTRS) Q2 FY26 earnings call

Viatris delivered a strong Q2 FY26, exceeding expectations with robust operational revenue growth and improved operating leverage, leading to a raise in full-year guidance across all key financial metrics. The company is prioritizing capital and resources towards long-term growth opportunities, advancing its pipeline with key regulatory approvals and clinical milestones, while also returning capital to shareholders and maintaining a disciplined approach to business development.